CPIX
CUMBERLAND PHARMACEUTICALS INC
Next earnings Aug 3, 2026
Last earnings +0.4% on 2026-05-05
$6.84
▲ 0.00%$6.84▲ +74.05%
over 1Y
L $1.90EODHDH $6.84
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+22.8%
1M+20.0%
3M+119.2%
YTD+71.9%
1Y+74.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Record revenue and finally positive operating cash flow, but 5 straight years of GAAP losses and a stock that already doubled on DMD hope.
Revenue (FY2025) $44.5M · FY2025
Cumberland is a seven-product specialty pharma (Caldolor, Vibativ, plus newly licensed Talicia) that just printed its best top line ever — FY2025 revenue of $44.5M, up 17.6% — while cutting its net loss 56% to -$2.84M. The most important number is operating cash flow of $4.93M (up from ~$0.5M): the base business now self-funds, current portion of debt is $0, and there are no legal proceedings. Management's 2025 highlights are real commercial progress — a CMS J-code for Caldolor, Vibativ approval in China and a Saudi launch, GPO contracts with Premier and Vizient. For a $102M market cap, a 2.3x P/S on a growing, cash-generative franchise is not demanding.
The other side is hard to ignore. Cumberland has not earned a GAAP profit in any of the last five years (-$3.5M, -$5.6M, -$6.3M, -$6.5M, -$2.8M), the accumulated deficit widened to -$26.8M, ROE is -11.4%, and liabilities/equity sits at 2.10x. Cash fell 36% to $11.4M despite positive operations, and shares grew 7.1% — so the balance sheet is thin and the company leans on dilution and a 157-month Nashville HQ lease running to 2035. This is a structurally low-margin business that depends on continually acquiring or licensing products to grow.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $35.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$7.68M | -$5.70M | -$9.55M | -$6.43M | -$2.79M |
| Net income | -$3.51M | -$5.57M | -$6.28M | -$6.48M | -$2.84M |
| Diluted EPS | -$0.24 | -$0.38 | -$0.44 | -$0.46 | -$0.19 |
| Net margin | -10.0% | -13.3% | -15.9% | -17.1% | -6.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$90.9M
EV / EBITDA67.1
EV / Sales2.0
EV / FCF18.8
P / FCF21.2
PEG (trailing)—
Earnings yield-2.8%
FCF yield4.7%
Quality & risk
ROIC (est.)-8.9%
Free cash flow$4.83M
Total debt$0.00
Net cash$11.4M
Altman Z-Score1.15 distress
Piotroski F-Score4/7
Capital returns
Buyback yield0.3%
Dividend yield (est.)—
Shareholder yield0.3%
Shares Δ YoY+7.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-06-25
Annual meeting vote results; routine director/auditor ratification
- 10-Q Quarterly report2026-05-08
Q1 2026 10-Q; specialty pharma, seven marketed brands, ifetroban pipeline
- 8-K Earnings results2026-05-05
Q1 FY26 results released; revenue continues post-Talicia growth
- 8-K Shareholder vote2026-04-24
Shareholder vote results filed; routine governance matters
- 8-K Material agreement2026-04-23
Signed material agreement + Reg FD disclosure; business/portfolio expansion
- DEF 14A Proxy statement2026-03-09
FY2025 10-K: revenue grew, loss narrowed, added Talicia to GI franchise
- 10-K Annual report2026-03-09
FY2025 10-K: revenue grew, loss narrowed, added Talicia to GI franchise
- 8-K Earnings results2026-03-03
FY2025 results: revenue +17.6% to $44.5M, net loss narrowed 56% to -$2.8M
- 8-K Other event2026-02-04
Other-event disclosure; likely ifetroban DMD top-line/program update
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-25open ↗DEFM14AFiling2026-05-26open ↗PREM14APeriod ending 2026-05-152026-05-15open ↗10-QPeriod ending 2026-03-312026-05-08open ↗8-KPeriod ending 2026-05-052026-05-05open ↗8-KPeriod ending 2026-04-212026-04-24open ↗DEFA14AFiling2026-04-23open ↗8-KPeriod ending 2026-04-222026-04-23open ↗4Period ending 2026-03-182026-03-20open ↗4Period ending 2026-03-182026-03-20open ↗4Period ending 2026-03-182026-03-20open ↗4Period ending 2026-03-182026-03-20open ↗
Frequently asked
- Is CUMBERLAND PHARMACEUTICALS INC (CPIX) a buy?
- CPIX currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Record revenue and finally positive operating cash flow, but 5 straight years of GAAP losses and a stock that already doubled on DMD hope.
- What is CUMBERLAND PHARMACEUTICALS INC's quality score?
- CPIX scores 56.21568627450981/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001087294, latest 10-Q filed 2026-05-08) · EODHD · analysis by claude-code · as of 6/30/2026, 11:57:29 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.